MiniMed: New Pumps Are Finally Winning Patients, But the Stock Has Priced Much of the Win

MiniMed is one of the newest public companies on your screen, and one of the easiest to misread. Medtronic spun its diabetes business out in an IPO in March 2026, pricing shares at $20 and keeping roughly 90% of the company for itself. The stock has climbed about 30% since the spring and now trades within a few dollars of its high, the market paying up on a plain story: after years of ceding ground, MiniMed's newest pumps and sensors are finally winning patients back.

The latest quarter is the first real proof that this is more than a launch-day narrative. MiniMed reported that U.S. revenue grew 13.1% in the three months through July 31, 2026 — a dramatic jump from the 1.5% it managed in the prior quarter — driven by the new MiniMed Flex smartphone-controlled pump and the Simplera and Instinct sensors that pair with it. Pump revenue rose 21.5% to $144 million, new pumps sold in the U.S. grew more than 20%, and the share of patients wearing both a MiniMed pump and a MiniMed continuous glucose monitor climbed to 69%, up five points in a year.

That last number is the one that matters most for the investment case. About 82% of MiniMed's revenue is recurring — the pumps are a one-time device sale, but the sensors and tubing patients reorder keep generating revenue every quarter. A rising "attachment rate" means new pump buyers are being converted into repeat revenue streams, which is how a medical device company turns a product win into durable economics.

Here is where the headline growth deserves a closer look. The 15.8% organic growth for the quarter includes an estimated four to six points that came from an extra week in the fiscal calendar, not from patients. Strip that out and growth was low-double-digit, and U.S. growth specifically was high single digits. None of that is bad — it is a genuine acceleration from the prior quarter's 8.7%. But it warns against compounding the quarterly pop.

Management's own guidance makes the point. For the full year MiniMed raised its forecast to about 10.5% organic revenue growth, up from about 10%, and that number still includes roughly a point and a half of extra-week benefit. In other words, the company is guiding to something like 9% underlying growth for the year even as the quarter just reported looks like 16%. A 5% stock jump on the print assumes the launch spike is the new run rate; the guidance itself says it is not.

The margin ramp is the real test

MiniMed's growth story now has to convert into profit, and that is the part not yet proven. The quarter reached roughly breakeven net income versus a $19 million loss a year earlier, and adjusted EBITDA margin was about 12.2% after stripping out accelerated investment and a currency charge. The gross margin beat expectations at 55.9%.

But the company is still burning cash rather than generating it. In the quarter it used $90 million of free cash flow; it was only about break-even-to-slightly-positive after excluding the $111 million it spent on separation and stand-up costs from the IPO. On a trailing-twelve-month basis, free cash flow is meaningfully negative. Management is targeting a 16% adjusted EBITDA margin for the full year, which requires most of the improvement to arrive in the second half — a back-half promise, not yet a delivered result.

The float deserves attention too. Because Medtronic still owns about nine of every ten shares, the ~$6.3 billion market cap rests on a thin slice of freely traded stock. A handful of changes in the price reflects trading in a small float, and a large part of MiniMed's value remains, for now, inside the parent company.

What the price already assumes

At about $22 a share, MiniMed trades at roughly twice trailing sales — cheaper than growth rival Insulet (Omnipod) at about 3x, and far below CGM leader Dexcom at about 6x, though those companies are solidly profitable and MiniMed is not. On an earnings basis MiniMed has no multiple yet; it has only just stopped losing money.

The business has cleared a real hurdle: a decade-old product line finally responded to a new-generation design, and U.S. growth went from stalled to accelerating on the evidence. The most useful question for a new holder is whether the proof has already been paid for. The stock sits near its highs on a quarter whose headline number was flattered by an extra week and whose own guidance projects a deceleration to roughly 9% underlying growth — all before the second-half margin and cash-flow ramp has been demonstrated.

That makes this a wait-and-see rather than a cheap-entry situation. The pump lineup is winning patients, and that is genuinely new. What has not yet been shown is that the win can pay for itself — in a 16% EBITDA margin delivered on schedule, in flat-to-positive free cash flow outside the one-time separation costs, and in U.S. growth that stays near double digits once the launch spike fades. Watch the second-half margins, and judge the stock after the next few quarters prove whether the new patients' recurring revenue is replacing the cash burn. It is too early to declare the price wrong either way.